SOMERSET, N.J., Oct. 29 /PRNewswire-FirstCall/ Alfacell Corporation (NASDAQ:ACEL) today announced that Lawrence A. Kenyon, executive vice president, chief financial officer and corporate secretary, will present an overview of the company's product development programs at 10:55 a.m. EDT on Nov. 5, 2007, at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference at the New York Palace Hotel in New York City.

The live Webcast of the presentation will be available on Alfacell's Web site at www.alfacell.com. A replay of the Webcast will be available online for 90 days.

About Alfacell Corporation

Alfacell Corporation is the first company to advance a biopharmaceutical product candidate that works in a manner similar to RNA interference (RNAi) through late-stage clinical trials. The product candidate, ONCONASE(R), is an RNase that overcomes the challenges of targeting RNA for therapeutic purposes while enabling the development of a new class of targeted therapies for cancer and other life-threatening diseases. In addition to an ongoing Phase IIIb study in malignant mesothelioma, Alfacell is conducting a Phase I/II trial of ONCONASE in non-small cell lung cancer (NSCLC) and other solid tumors. For more information, visit www.alfacell.com.

Safe Harbor

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, uncertainties involved in transitioning from concept to product, uncertainties involving the ability of the company to finance research and development activities, potential challenges to or violations of patents, uncertainties regarding the outcome of clinical trials, the company's ability to secure necessary approvals from regulatory agencies, dependence upon third-party vendors, and other risks discussed in the company's periodic filings with the Securities and Exchange Commission. By making these forward-looking statements, the company undertakes no obligation to update these statements for revisions or changes after the date of this release.

     Media Contact:                      Investor Contact:
     David Schull or Wendy Lau           Andreas Marathovouniotis
     Russo Partners                      Russo Partners
     212-845-4271                        212-845-4253
     david.schull@russopartnersllc.com   andreas.marathis@russopartnersllc.comwendy.lau@russopartnersllc.com

Source: Alfacell Corporation